Gadoteridol
Appearance
![]() | |
Clinical data | |
---|---|
Other names | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H29GdN4O7 |
Molar mass | 558.69 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.
References
- Bracco Diagnostic Inc. (May 2007). "Gadoteridol (ProHance) prescribing information (revised May 2007)". DailyMed. U.S. National Library of Medicine. Retrieved 2008-07-13.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.